Provided by Tiger Trade Technology Pte. Ltd.

ArriVent BioPharma

31.35
+3.0910.93%
Post-market: 31.350.00000.00%19:30 EDT
Volume:961.65K
Turnover:29.47M
Market Cap:1.55B
PE:-8.48
High:31.52
Open:28.64
Low:28.64
Close:28.26
52wk High:35.83
52wk Low:17.00
Shares:49.31M
Float Shares:32.11M
Volume Ratio:2.57
T/O Rate:3.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6975
EPS(LYR):-4.3239
ROE:-53.25%
ROA:-33.11%
PB:4.21
PE(LYR):-7.25

Loading ...

Arrivent Biopharma, Inc. : H.c. Wainwright Raises Target Price to $47 from $44

THOMSON REUTERS
·
Aug 17

U.S. Research Roundup- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies

Reuters
·
Aug 17

ArriVent BioPharma (AVBP) Could Be 56% Undervalued After The Allist China Licensing Deal

Simply Wall St.
·
Aug 16

ArriVent BioPharma: Pipeline Progress and Funding Strength Support Buy Rating and Unchanged $42 Price Target

TIPRANKS
·
Aug 13

ArriVent BioPharma Price Target Maintained with a $42.00/Share by BTIG

Dow Jones
·
Aug 13

ArriVent BioPharma, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

ArriVent Biopharma Releases Corporate Presentation on Late-Stage Oncology Pipeline Led by Firmonertinib in EGFR-Mutant NSCLC

Reuters
·
Aug 13

ArriVent inks China partnership for ARR-002 development

TIPRANKS
·
Aug 13

ArriVent BioPharma Q2 EPS $(1.05) Misses $(0.99) Estimate

Benzinga Earnings
·
Aug 13

Press Release: ArriVent BioPharma Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 13

Analysts Are Bullish on These Healthcare Stocks: Astrana Health (ASTH), ArriVent BioPharma, Inc. (AVBP)

TIPRANKS
·
Jul 14

ArriVent BioPharma Stockholders Back Board and Auditor Slate

TIPRANKS
·
Jun 23

ArriVent Biopharma shareholders elect Class II directors at annual meeting

Reuters
·
Jun 23

ArriVent’s MRG007 Phase I Trial Progress Adds Long-Term Option Value for AVBP Investors

TIPRANKS
·
Jun 05

Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Mineralys Therapeutics, Inc. (MLYS) and ArriVent BioPharma, Inc. (AVBP)

TIPRANKS
·
Jun 04

Guggenheim Remains a Buy on ArriVent BioPharma, Inc. (AVBP)

TIPRANKS
·
Jun 02

Analyst Reiterates Buy on ArriVent, Maintains $42 Price Target on Firlotinib Confidence After Sunvozertinib Data

TIPRANKS
·
Jun 01

ArriVent BioPharma Is Maintained at Buy by Truist Securities

Dow Jones
·
May 30

Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), ArriVent BioPharma, Inc. (AVBP)

TIPRANKS
·
May 20

LifeSci Capital Remains a Buy on ArriVent BioPharma, Inc. (AVBP)

TIPRANKS
·
May 18